Limits...
Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.

Dong LL, Chen LM, Wang WM, Zhang LM - Diagn Pathol (2015)

Bottom Line: The correlation between the miR-124 levels and the clinicopathological factors of the patients was also analyzed.Low miR-124 expression level was significantly associated with advanced TNM stage (P = 0.011), lymph node metastasis (P = 0.012), and poorer pathological differentiation (P = 0.023).These findings proved that the decreased expression of miR-124 might be associated with tumor progression and poor prognosis in patients with breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Yantai Yuhuangding Hospital, 20 Yuhuangding East Road, Yantai, Shandong, 264000, China. yt_dongliangliang@126.com.

ABSTRACT

Background: MicroRNA-124 (miR-124) has been reported to be downregulated in breast cancer. However, its clinical significance and prognostic value in breast cancer have not been extensively studied.

Methods: The tissue expression levels of miR-124 were measured using quantitative real-time PCR in 133 breast cancer patients. The correlation between the miR-124 levels and the clinicopathological factors of the patients was also analyzed. Survival and Cox proportional-hazards regression analyses were performed to determine the correlation between miR-124 expression levels and prognosis in the patients.

Results: Quantitative real-time PCR analysis showed that miR-124 had lower expression in breast cancer specimens than that in matched adjacent normal breast tissues (0.39 ± 0.16 vs. 1.00 ± 0.39; P < 0.05). Low miR-124 expression level was significantly associated with advanced TNM stage (P = 0.011), lymph node metastasis (P = 0.012), and poorer pathological differentiation (P = 0.023). A significant difference was found that breast cancer patients with low miR-124 expression level had distinctly shorter overall survival than patients with high miR-124 expression level (63.8% vs. 35.2%, P = 0.03). Furthermore, multivariate analysis of the prognosis factors with a Cox proportional hazards model confirmed that low miR-124 expression was a significant independent predictor of poor survival in breast cancer (HR = 3.16, 95% CI: 1.79-9.13, P = 0.017).

Conclusion: These findings proved that the decreased expression of miR-124 might be associated with tumor progression and poor prognosis in patients with breast cancer.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3752603721493544.

No MeSH data available.


Related in: MedlinePlus

Relationship between miR-124 expression and survival time in breast cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4430031&req=5

Fig2: Relationship between miR-124 expression and survival time in breast cancer.

Mentions: Kaplan–Meier method and log-rank test were used to evaluate the differences of overall survival between low-expression group and high-expression group. A significant difference was found that breast cancer patients with low miR-124 expression level had distinctly shorter overall survival than patients with high miR-124 expression level (63.8% vs. 35.2%, P = 0.03, shown in Figure 2). Univariate and multivariate analyses were utilized to evaluate whether the miR-124 expression level and various clinicopathological features were independent prognostic parameters of breast cancer patient outcomes. The results of analysis are shown in Table 2. A multivariate analysis of the prognosis factors with a Cox proportional hazards model confirmed that low miR-124 expression was a significant independent predictor of poor survival in breast cancer (HR = 3.16, 95% CI: 1.79-9.13, P = 0.017).Figure 2


Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.

Dong LL, Chen LM, Wang WM, Zhang LM - Diagn Pathol (2015)

Relationship between miR-124 expression and survival time in breast cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4430031&req=5

Fig2: Relationship between miR-124 expression and survival time in breast cancer.
Mentions: Kaplan–Meier method and log-rank test were used to evaluate the differences of overall survival between low-expression group and high-expression group. A significant difference was found that breast cancer patients with low miR-124 expression level had distinctly shorter overall survival than patients with high miR-124 expression level (63.8% vs. 35.2%, P = 0.03, shown in Figure 2). Univariate and multivariate analyses were utilized to evaluate whether the miR-124 expression level and various clinicopathological features were independent prognostic parameters of breast cancer patient outcomes. The results of analysis are shown in Table 2. A multivariate analysis of the prognosis factors with a Cox proportional hazards model confirmed that low miR-124 expression was a significant independent predictor of poor survival in breast cancer (HR = 3.16, 95% CI: 1.79-9.13, P = 0.017).Figure 2

Bottom Line: The correlation between the miR-124 levels and the clinicopathological factors of the patients was also analyzed.Low miR-124 expression level was significantly associated with advanced TNM stage (P = 0.011), lymph node metastasis (P = 0.012), and poorer pathological differentiation (P = 0.023).These findings proved that the decreased expression of miR-124 might be associated with tumor progression and poor prognosis in patients with breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Yantai Yuhuangding Hospital, 20 Yuhuangding East Road, Yantai, Shandong, 264000, China. yt_dongliangliang@126.com.

ABSTRACT

Background: MicroRNA-124 (miR-124) has been reported to be downregulated in breast cancer. However, its clinical significance and prognostic value in breast cancer have not been extensively studied.

Methods: The tissue expression levels of miR-124 were measured using quantitative real-time PCR in 133 breast cancer patients. The correlation between the miR-124 levels and the clinicopathological factors of the patients was also analyzed. Survival and Cox proportional-hazards regression analyses were performed to determine the correlation between miR-124 expression levels and prognosis in the patients.

Results: Quantitative real-time PCR analysis showed that miR-124 had lower expression in breast cancer specimens than that in matched adjacent normal breast tissues (0.39 ± 0.16 vs. 1.00 ± 0.39; P < 0.05). Low miR-124 expression level was significantly associated with advanced TNM stage (P = 0.011), lymph node metastasis (P = 0.012), and poorer pathological differentiation (P = 0.023). A significant difference was found that breast cancer patients with low miR-124 expression level had distinctly shorter overall survival than patients with high miR-124 expression level (63.8% vs. 35.2%, P = 0.03). Furthermore, multivariate analysis of the prognosis factors with a Cox proportional hazards model confirmed that low miR-124 expression was a significant independent predictor of poor survival in breast cancer (HR = 3.16, 95% CI: 1.79-9.13, P = 0.017).

Conclusion: These findings proved that the decreased expression of miR-124 might be associated with tumor progression and poor prognosis in patients with breast cancer.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3752603721493544.

No MeSH data available.


Related in: MedlinePlus